ClinicalTrials.gg
Not yet recruitingNCT07777263Updated Aug 20, 2026

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)

A Phase 3 interventional study of ZOLADEX 10.8 mg in High Risk Prostate Cancer, sponsored by Dr. Tamim Niazi. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Dr. Tamim Niazi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing goserelin in Prostatic Neoplasms — 3 open to participants now, 4 under way, 3 of them phase 3. Goserelin · Prostatic Neoplasms.

Planned enrollment
8th of 29
600 · median 110
Started
2026
the only one that year
Phase 3
15 of 31
2 open now
Registered
31st of 31
by date
Lead sponsor
1 of 31
Dr. Tamim Niazi

Among the 31 studies testing goserelin in Prostatic Neoplasms, this one is the 8th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2026, is one of 15 in phase 3, and was the 31st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 31 studies testing goserelin in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing goserelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

High-risk prostate cancer is usually treated with a combination of radiation therapy and hormone therapy (ADT). Radiation destroys cancer cells, while ADT lowers testosterone, a hormone that prostate cancer cells need to grow. Together, these treatments help control the cancer.

ADT is usually given for 18 to 24 months, but it can cause side effects that may affect quality of life.

Some people with high-risk prostate cancer may do just as well with a shorter course of ADT. This study will identify people who are most likely to benefit from shorter treatment using imaging scans and tumor tests. It will then evaluate whether a shorter course of ADT works as well as the standard treatment while reducing long-term side effects.

03

Conditions studied

  • High Risk Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • Zoladex
  • Jewish General Hospital
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Able to understand and sign form (ICF);

      • Males aged ≥ 18 years;
      • confirmed adenocarcinoma of the prostate;
      • Participants with high-risk prostate cancer according to either of the following:

        a) High-risk disease - at least one of the following: i. T3a ii. Gleason 8 or less iii. PSA ≤ 30 ng/mL

iv. Gleason 9 (4+5) not more than 30% of the (e.g. a 10-needle biopsy can only have a maximum of 3 x 9 [4+5]);

  • PTEN-proficient tumor confirmed by CLIA-certified immunohistochemistry (IHC);
  • PSMA-PET within 90 days prior to randomization: negative for nodal or distant disease.
  • Candidate for definitive radiation to prostate and pelvis;
  • (ECOG) performance status of 0-2 or performance status of ≥70%;
  • Testosterone ≥150 ng/dL or 5 nmol/L;
  • Adequate hematologic, renal, liver function ( ≥10 g/dL, ≥1.5x10⁹/L, ≥100x10⁹/L);
  • Judged to be medically fit for ADT and RT;
  • Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
  • Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for 3 months after the end of the study treatment.

Exclusion criteria

Exclusion Criteria:

    • Prior local or systemic therapy for prostate cancer (e.g. ADT, chemotherapy or novel Androgen Receptor Inhibitors [ARIs]);

      • PSMA-PET positive nodal or distant ;
      • PTEN loss or equivocal by IHC (at least more than 50%);
      • Evidence of nodal or distant metastases on conventional imaging;
      • Prior pelvic radiation or prostate surgery interfering with RT (except /TURP);
      • \<5 years regardless of the prostate cancer;
      • Severe concurrent disease, infection, or co-morbidity that would make the patient inappropriate for enrollment (e.g. cardiovascular disease, hypertension, diabetes, etc);
      • Uncontrolled cardiovascular disease including:

        • Myocardial infarction within 6 months;
        • Unstable angina;
        • Congestive Heart Failure: (NYHA) class III or IV;
        • Severe arrhythmia;
      • Active severe infection or ;
      • Active second within 5 years with the exception of:

        • Non-melanoma skin cancer;
        • Chronic Lymphocytic Leukemia (CLL) that is stable and not actively treated;
      • Any condition compromising adherence to the protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Arm 1 (experimental): 12 months of ADT + Radiotherapy

    Zoladex is given for 12 months instead of 24

    Drug: ZOLADEX 10.8 mg

  • Active comparator
    Arm 2 (standard of care): 24 months of ADT + Radiotherapy

    Drug: ZOLADEX 10.8 mg

Interventions

  • The purpose of the study is to identify a subset of patient that may benefit to have a shorter Zoladex treatment (12 months vs 24 months)

06

What researchers measure

Primary outcomes

  1. 5-year biochemical failure-free survival (bFFS)

    Time from ADT initiation to time of first occurrence of biochemical failure (per Phoenix definition: PSA nadir + 2 ng/ml)

    Time frame: 5 years

Secondary outcomes

  1. Metastasis-free survival

    The first occurrence of distant progression or death from ADT initiation

    Time frame: 5-8 years

  2. Overall survival

    The time from ADT initiation to the time of death from any cause.

    Time frame: 5-8 years

  3. Prostate cancer-specific mortality

    The time from ADT initiation to the time of death from prostate cancer

    Time frame: 5-8 years

  4. 8-year biochemical failure-free survival (bFFS)

    Time from ADT initiation to time of first occurrence of biochemical failure (per Phoenix definition: PSA nadir + 2 ng/ml)

    Time frame: 8 years

  5. Toxicity - Acute

    To determine acute toxicity due to treatment using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0

    Time frame: 5 years

  6. Toxicity - Late

    To determine late toxicity due to treatment using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0

    Time frame: 8 years

  7. Quality of Life - General

    Evaluate the impact of the treatment on the patient's quality of life using the FACT-P questionnaire

    Time frame: 5-8 years

  8. Quality of Life - Pain

    Evaluate the impact of the treatment on the patient's quality of life using the Brief Pain Inventory (BPI) questionnaire

    Time frame: 5-8 years

  9. Quality of Life - Fatigue

    Evaluate the impact of the treatment on the patient's quality of life using the Brief Fatigue Inventory (BFI) questionnaire

    Time frame: 5-8 years

  10. Testosterone Recuperation

    Time from ADT completion to the return of serum-testosterone to non-castrate or normal baseline level

    Time frame: 5-8 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2035, 108 months later.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 108 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Aug 20, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2035
CompletionEst.
Oct 2040
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07777263
Lead sponsor
Dr. Tamim Niazi
Responsible party
Dr. Tamim Niazi (Principal Investigator, Sir Mortimer B. Davis - Jewish General Hospital) — Sponsor-investigator
First posted
Aug 20, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2035 (estimated)
Completion
Oct 2040 (estimated)
Last update
Aug 20, 2026

Study contacts

Mélanie Criqui, PhD
Contact
melanie.criqui.ccomtl@ssss.gouv.qc.ca
514340822 ext. 26771
Paola Diego, Nurse
Contact
paola.diego.ccomtl@ssss.gouv.qc.ca
5143408222 ext. 24404

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion